口服泼尼松龙治疗早期弥漫性皮肤型系统性硬化症(PRedSS)的II期随机对照试验
PRedSS为II期多中心双盲随机对照试验,因新冠疫情转为开放标签,35例早期弥漫性皮肤型系统性硬化症患者随机接受泼尼松龙(约0.3 mg/kg)或安慰剂/对照治疗6个月。3个月时HAQ-DI和mRSS差异无统计学显著性,泼尼松龙组疼痛、焦虑和无助感显著减轻;无肾危象发生,但样本量小,试验提前终止、把握度不足,结果视为不确定,需进一步随机试验。
要点
- 3个月时HAQ-DI校正均差-0.10(97.5%CI:-0.29,0.10),P=0.254,未达统计学显著。
- 3个月时mRSS校正均差-3.90(97.5%CI:-8.83,1.03),P=0.070,未达统计学显著。
- 泼尼松龙组3个月时疼痛(P=0.027)、焦虑(P=0.018)和无助感(P=0.040)较对照组显著减轻。
核心结论
- PRedSS试验因新冠疫情提前终止,把握度不足,结果解读需谨慎并视为不确定,表明需进一步随机试验。
研究设计与样本
- PRedSS为II期多中心双盲随机对照试验,因新冠疫情转为开放标签。
- 患者随机接受泼尼松龙(约0.3 mg/kg)或匹配安慰剂(开放标签阶段为无治疗)治疗6个月。
- 共35例患者被随机分组(泼尼松龙组17例,安慰剂/对照组18例),目标招募72例。
- 共同主要终点为3个月时HAQ残疾指数(HAQ-DI)和改良Rodnan皮肤评分(mRSS)。
主要发现
- 3个月时HAQ-DI校正均差为-0.10(97.5%CI:-0.29,0.10),P=0.254,未达统计学显著。
- 3个月时mRSS校正均差为-3.90(97.5%CI:-8.83,1.03),P=0.070,未达统计学显著。
- 泼尼松龙组3个月时疼痛(P=0.027)、焦虑(P=0.018)和无助感(P=0.040)较对照组显著减轻。
- 无肾危象发生,但样本量小。
局限性
- 样本量小。
- 试验因新冠疫情提前终止,把握度不足。
- 结果视为不确定,需进一步随机试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Although the painful and disabling features of early diffuse cutaneous SSc (dcSSc) have an inflammatory basis and could respond to corticosteroids, corticosteroids are a risk factor for scleroderma renal crisis. Whether or not they should be prescribed is therefore highly contentious. Our aim was to examine safety and efficacy of moderate-dose prednisolone in early dcSSc. METHODS: PRedSS set out as a Phase II, multicentre, double-blind randomized controlled trial, converted to open-label during the Covid-19 pandemic. Patients were randomized to receive either prednisolone (∼0.3 mg/kg) or matching placebo (or no treatment during open-label) for 6 months. Co-primary endpoints were the HAQ Disability Index (HAQ-DI) and modified Rodnan skin score (mRSS) at 3 months. Over 20 secondary endpoints included patient reported outcome measures reflecting pain, itch, fatigue, anxiety and depression, and helplessness. Target recruitment was 72 patients. RESULTS: Thirty-five patients were randomized (17 prednisolone, 18 placebo/control). The adjusted mean difference between treatment groups at 3 months in HAQ-DI score was -0.10 (97.5% CI: -0.29, 0.10), P = 0.254, and in mRSS -3.90 (97.5% CI: -8.83, 1.03), P = 0.070, both favouring prednisolone but not significantly. Patients in the prednisolone group experienced significantly less pain (P = 0.027), anxiety (P = 0.018) and helplessness (P = 0.040) than control patients at 3 months. There were no renal crises, but sample size was small. CONCLUSION: PRedSS was terminated early primarily due to the Covid-19 pandemic, and so was underpowered. Therefore, interpretation must be cautious and results considered inconclusive, indicating the need for a further randomized trial. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT03708718.
引用
- Griffiths-Jones DJ, Garcia YS, Ryder WD, et al. A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS). Rheumatology (Oxford). 2023. PMID: 36637209. doi:10.1093/rheumatology/kead012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。